I guess we will just have to wait and see how that turns out. The FDA WANTS to approve something to address AD. These results are better than anything else on the immediate horizon. It is that simple.
The SOC is very low, so low that the latest drug proposed by Biogen slows the rate of decline by 27% if you accept what it has said. The Anavex results are considerably better than that.